<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">37753372</PMID><DateRevised><Year>2023</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-889X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in molecular biosciences</Title><ISOAbbreviation>Front Mol Biosci</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 infection as a potential risk factor for the development of cancer.</ArticleTitle><Pagination><StartPage>1260776</StartPage><MedlinePgn>1260776</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1260776</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmolb.2023.1260776</ELocationID><Abstract><AbstractText>The COVID-19 pandemic has a significant impact on public health and the estimated number of excess deaths may be more than three times higher than documented in official statistics. Numerous studies have shown an increased risk of severe COVID-19 and death in patients with cancer. In addition, the role of SARS-CoV-2 as a potential risk factor for the development of cancer has been considered. Therefore, in this review, we summarise the available data on the potential effects of SARS-CoV-2 infection on oncogenesis, including but not limited to effects on host signal transduction pathways, immune surveillance, chronic inflammation, oxidative stress, cell cycle dysregulation, potential viral genome integration, epigenetic alterations and genetic mutations, oncolytic effects and reactivation of dormant cancer cells. We also investigated the potential long-term effects and impact of the antiviral therapy used in COVID-19 on cancer development and its progression.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Ogarek, Oboza, Olszanecka-Glinianowicz and Kocelak.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ogarek</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Pathophysiology Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, The Medical University of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oboza</LastName><ForeName>Paulina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Students' Scientific Society at the Pathophysiology Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, The Medical University of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olszanecka-Glinianowicz</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, The Medical University of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kocelak</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pathophysiology Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, The Medical University of Silesia, Katowice, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Mol Biosci</MedlineTA><NlmUniqueID>101653173</NlmUniqueID><ISSNLinking>2296-889X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">excess death</Keyword><Keyword MajorTopicYN="N">long Covid</Keyword><Keyword MajorTopicYN="N">oncogenesis</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>27</Day><Hour>3</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37753372</ArticleId><ArticleId IdType="pmc">PMC10518417</ArticleId><ArticleId IdType="doi">10.3389/fmolb.2023.1260776</ArticleId><ArticleId IdType="pii">1260776</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahrends T., Borst J. (2018). The opposing roles of CD4+ T cells in anti-tumour immunity. Immunology 154, 582&#x2013;592. 10.1111/imm.12941</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12941</ArticleId><ArticleId IdType="pmc">PMC6050207</ArticleId><ArticleId IdType="pubmed">29700809</ArticleId></ArticleIdList></Reference><Reference><Citation>Akgul C. (2009). Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol. Life Sci. 66, 1326&#x2013;1336. 10.1007/s00018-008-8637-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-008-8637-6</ArticleId><ArticleId IdType="pmc">PMC11131550</ArticleId><ArticleId IdType="pubmed">19099185</ArticleId></ArticleIdList></Reference><Reference><Citation>Akram N., Imran M., Noreen M., Ahmaed F., Atif M., Fatima Z., et al. (2017). Oncogenic role of tumor viruses in humans. Viral Immunol. 30, 20&#x2013;27. 10.1089/vim.2016.0109</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2016.0109</ArticleId><ArticleId IdType="pubmed">27830995</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Obeed O. A., Alkhayal K., Sheikh A., Zubaidi A., Waali-Mohammad M., Boushey R., et al. (2014). Increased expression of tumor necrosis factor-&#x3b1; is associated with advanced colorectal cancer stages. World J. Gastroenterol. 20, 18390&#x2013;18396. 10.3748/wjg.v20.i48.18390</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i48.18390</ArticleId><ArticleId IdType="pmc">PMC4277977</ArticleId><ArticleId IdType="pubmed">25561807</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali M. D., Wani S., Masoodi M., Khan N., Shivakumar H., Osmani R., et al. (2022). Global effect of COVID-19 pandemic on cancer patients and its treatment: A systematic review. Clin. Complement. Med. Pharmacol. 2, 100041. 10.1016/j.ccmp.2022.100041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccmp.2022.100041</ArticleId><ArticleId IdType="pmc">PMC9035683</ArticleId><ArticleId IdType="pubmed">36377228</ArticleId></ArticleIdList></Reference><Reference><Citation>Alpalh&#xe3;o M., Ferreira J. A., Filipe P. (2020). Persistent SARS-CoV-2 infection and the risk for cancer. Med. Hypotheses 143, 109882. 10.1016/j.mehy.2020.109882</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.109882</ArticleId><ArticleId IdType="pmc">PMC7831646</ArticleId><ArticleId IdType="pubmed">32485314</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson L., Yoshida-Montezuma Y., Dewart N., Jalil E., Khattar J., De Rubeis V., et al. (2023). Obesity and weight change during the COVID-19 pandemic in children and adults: A systematic review and meta-analysis. Obes. Rev. 24, e13550. 10.1111/obr.13550</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/obr.13550</ArticleId><ArticleId IdType="pubmed">36721999</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson N. M., Simon M. C. (2020). The tumor microenvironment. Curr. Biol. 30, R921&#x2013;5. 10.1016/j.cub.2020.06.081</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2020.06.081</ArticleId><ArticleId IdType="pmc">PMC8194051</ArticleId><ArticleId IdType="pubmed">32810447</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9; P., Denis C., Soulas C., Bourbon-Cailet C., Lopez J., Arnoux T., et al. (2018). Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731&#x2013;1743. 10.1016/j.cell.2018.10.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.10.014</ArticleId><ArticleId IdType="pmc">PMC6292840</ArticleId><ArticleId IdType="pubmed">30503213</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz M., Fatima R., Assaly R. (2020). Elevated interleukin-6 and severe COVID-19: A meta-analysis. J. Med. Virol. 92, 2283&#x2013;2285. 10.1002/jmv.25948</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25948</ArticleId><ArticleId IdType="pmc">PMC7267383</ArticleId><ArticleId IdType="pubmed">32343429</ArticleId></ArticleIdList></Reference><Reference><Citation>Baghban R., Roshangar L., Jahanban-Esfahlan R., Seidi K., Ebrahimi-Kalan A., Jaymand M., et al. (2020). Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal 18, 59. 10.1186/s12964-020-0530-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-020-0530-4</ArticleId><ArticleId IdType="pmc">PMC7140346</ArticleId><ArticleId IdType="pubmed">32264958</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Z., Cao Y., Liu W., Li J. (2021). The SARS-CoV-2 nucleocapsid protein and its role in viral structure, biological functions, and a potential target for drug or vaccine mitigation. Viruses 13, 1115. 10.3390/v13061115</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13061115</ArticleId><ArticleId IdType="pmc">PMC8227405</ArticleId><ArticleId IdType="pubmed">34200602</ArticleId></ArticleIdList></Reference><Reference><Citation>Baitsch L., Baumgaertner P., Dev&#xea;vre E., Raghav S. K., Legat A., Barba L., et al. (2011). Exhaustion of tumor-specific CD8&#x207a; T cells in metastases from melanoma patients. J. Clin. Invest. 121, 2350&#x2013;2360. 10.1172/JCI46102</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI46102</ArticleId><ArticleId IdType="pmc">PMC3104769</ArticleId><ArticleId IdType="pubmed">21555851</ArticleId></ArticleIdList></Reference><Reference><Citation>Balkwill F. (2006). TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 25, 409&#x2013;416. 10.1007/s10555-006-9005-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10555-006-9005-3</ArticleId><ArticleId IdType="pubmed">16951987</ArticleId></ArticleIdList></Reference><Reference><Citation>Balkwill F. (2009). Tumour necrosis factor and cancer. Nat. Rev. Cancer 9, 361&#x2013;371. 10.1038/nrc2628</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2628</ArticleId><ArticleId IdType="pubmed">19343034</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering A. V., van Zon S. K. R., Hartman T. C., Rosmalen J. G. M. (2022). Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet 400, 452&#x2013;461. 10.1016/S0140-6736(22)01214-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Balmeh N., Mahmoudi S., Mohammadi N., Karabedianhajiabadi A. (2020). Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors. Inf. Med. Unlocked 20, 100407. 10.1016/j.imu.2020.100407</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imu.2020.100407</ArticleId><ArticleId IdType="pmc">PMC7411426</ArticleId><ArticleId IdType="pubmed">32835083</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes B. J., Adrover J. M., Baxter-Stoltzfus A., Borczuk A., Cools-Lartigue J., Crawford J. M., et al. (2020). Targeting potential drivers of COVID-19: neutrophil extracellular traps. J. Exp. Med. 217, e20200652. 10.1084/jem.20200652</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200652</ArticleId><ArticleId IdType="pmc">PMC7161085</ArticleId><ArticleId IdType="pubmed">32302401</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty G. L., Gladney W. L. (2015). Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res. 21, 687&#x2013;692. 10.1158/1078-0432.CCR-14-1860</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-14-1860</ArticleId><ArticleId IdType="pmc">PMC4334715</ArticleId><ArticleId IdType="pubmed">25501578</ArticleId></ArticleIdList></Reference><Reference><Citation>Behura A., Naik L., Patel S., Das M., Kumar A., Mishra A., et al. (2023). Involvement of epigenetics in affecting host immunity during SARS-CoV-2 infection. Biochim. Biophys. Acta Mol. Basis Dis. 1869, 166634. 10.1016/j.bbadis.2022.166634</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2022.166634</ArticleId><ArticleId IdType="pmc">PMC9790847</ArticleId><ArticleId IdType="pubmed">36577469</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyazit Y., Aksu S., Haznedaroglu I., Keklli M., Misirlioglu M., Tuncer S., et al. (2007). Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia. J. Natl. Med. Assoc. 99, 57&#x2013;63. 10.1182/blood.V106.11.4567.4567</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V106.11.4567.4567</ArticleId><ArticleId IdType="pmc">PMC2569610</ArticleId><ArticleId IdType="pubmed">17304969</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj K., Liu P., Leibowitz J. L., Kao C. C. (2012). The coronavirus endoribonuclease Nsp15 interacts with retinoblastoma tumor suppressor protein. J. Virol. 86, 4294&#x2013;4304. 10.1128/JVI.07012-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.07012-11</ArticleId><ArticleId IdType="pmc">PMC3318636</ArticleId><ArticleId IdType="pubmed">22301153</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D., Nilsson-Payant B., Liu W. C., Uhl S., Hoagland D., Moller R., et al. (2020). Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036&#x2013;1045. 10.1016/j.cell.2020.04.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouche C., Quail D. F. (2023). Fueling the tumor microenvironment with cancer-associated adipocytes. Cancer Res. 83, 1170&#x2013;1172. 10.1158/0008-5472.CAN-23-0505</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-23-0505</ArticleId><ArticleId IdType="pubmed">37057599</ArticleId></ArticleIdList></Reference><Reference><Citation>Braicu C., Buse M., Busuioc C., Drula R., Gulai D., Raduly L., et al. (2019). A comprehensive review on mapk: A promising therapeutic target in cancer. Cancers (Basel) 11, 1618. 10.3390/cancers11101618</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11101618</ArticleId><ArticleId IdType="pmc">PMC6827047</ArticleId><ArticleId IdType="pubmed">31652660</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs E., Ward W., Rey S., Law D., Nelson K., Bois M., et al. (2021). Assessment of potential SARS-CoV-2 virus integration into human genome reveals no significant impact on RT-qPCR COVID-19 testing. Proc. Natl. Acad. Sci. U. S. A. 118, e2113065118. 10.1073/pnas.2113065118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2113065118</ArticleId><ArticleId IdType="pmc">PMC8612208</ArticleId><ArticleId IdType="pubmed">34702741</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown M. C., Holl E. K., Boczkowski D., Dobrikova E., Mosaheb M., Chandramohan V., et al. (2017). Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen&#x2013;specific CTLs. Sci. Transl. Med. 9, eaan4220. 10.1126/scitranslmed.aan4220</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aan4220</ArticleId><ArticleId IdType="pmc">PMC6034685</ArticleId><ArticleId IdType="pubmed">28931654</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty C., Sharma A. R., Bhattacharya M., Lee S. S. (2022). A detailed overview of immune escape, antibody escape, partial vaccine escape of SARS-CoV-2 and their emerging variants With escape mutations. Front. Immunol. 13, 801522. 10.3389/fimmu.2022.801522</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.801522</ArticleId><ArticleId IdType="pmc">PMC8863680</ArticleId><ArticleId IdType="pubmed">35222380</ArticleId></ArticleIdList></Reference><Reference><Citation>Challenor S., Tucker D. (2021). SARS-CoV-2-induced remission of Hodgkin lymphoma. Br. J. Haematol. 192, 415. 10.1111/bjh.17116</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17116</ArticleId><ArticleId IdType="pubmed">33386647</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi S. C., Pozzilli P. (2022). COVID-19 induced diabetes: A novel presentation. Diabetes. Res. Clin. Pract. 191, 110034. 10.1016/j.diabres.2022.110034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2022.110034</ArticleId><ArticleId IdType="pmc">PMC9355745</ArticleId><ArticleId IdType="pubmed">35940303</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Q., Bournazou E., Sansone P., Berishaj M., Gao S., Daly L., et al. (2013). The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 15, 848&#x2013;862. 10.1593/neo.13706</Citation><ArticleIdList><ArticleId IdType="doi">10.1593/neo.13706</ArticleId><ArticleId IdType="pmc">PMC3689247</ArticleId><ArticleId IdType="pubmed">23814496</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R., Fehr A., Vijay R., Mack M., Zhao J., Meyerholz D., et al. (2016). Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 19, 181&#x2013;193. 10.1016/j.chom.2016.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2016.01.007</ArticleId><ArticleId IdType="pmc">PMC4752723</ArticleId><ArticleId IdType="pubmed">26867177</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhry G. E., Md Akim A., Sung Y. Y., Sifzizul T. M. T. (2022). Cancer and apoptosis: the apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics. Front. Pharmacol. 13, 842376. 10.3389/fphar.2022.842376</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.842376</ArticleId><ArticleId IdType="pmc">PMC9399632</ArticleId><ArticleId IdType="pubmed">36034846</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan V. P., Martin J. D., Liu H., Laccore D. A., Jain S. R., Kozin S. V., et al. (2013). Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4, 2516. 10.1038/ncomms3516</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3516</ArticleId><ArticleId IdType="pmc">PMC3806395</ArticleId><ArticleId IdType="pubmed">24084631</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-MacGregor M., Lei X., Zhao H., Scheet P., Giordano S. H. (2022). Evaluation of COVID-19 mortality and adverse outcomes in US patients With or Without cancer. JAMA Oncol. 8, 69&#x2013;78. 10.1001/jamaoncol.2021.5148</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2021.5148</ArticleId><ArticleId IdType="pmc">PMC8554684</ArticleId><ArticleId IdType="pubmed">34709356</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Dai L., Barrett L., Post S. R., Qin Z., et al. (2021). SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus. Commun. Biol. 4, 682. 10.1038/s42003-021-02220-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02220-z</ArticleId><ArticleId IdType="pmc">PMC8175744</ArticleId><ArticleId IdType="pubmed">34083759</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Dai L., Kendrick S., Post S. R., Qin Z. (2022). The anti-COVID-19 drug remdesivir promotes oncogenic herpesvirus reactivation through regulation of intracellular signaling pathways. Antimicrob. Agents Chemother. 66, e0239521. 10.1128/aac.02395-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.02395-21</ArticleId><ArticleId IdType="pmc">PMC8923226</ArticleId><ArticleId IdType="pubmed">35041508</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T., Wu D., Chen W., Yang D., Chen G., Ma K., et al. (2020). Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368, m1091. 10.1136/bmj.m1091</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1091</ArticleId><ArticleId IdType="pmc">PMC7190011</ArticleId><ArticleId IdType="pubmed">32217556</ArticleId></ArticleIdList></Reference><Reference><Citation>Choong O. K., Jakobsson R., Bergdahl A. G., Brunet S., Ka&#xa8;rmander A., Waldenstro&#xa8;m J., et al. (2023). SARS-CoV-2 replicates and displays oncolytic properties in clear cell and papillary renal cell carcinoma. PLoS ONE 18, e0279578. 10.1371/journal.pone.0279578</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0279578</ArticleId><ArticleId IdType="pmc">PMC9810192</ArticleId><ArticleId IdType="pubmed">36595529</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortellini A., Salazar R., Gennari A., Aguilar-Company J., Bower M., Bertuzzi A., et al. (2022). Persistence of long-term COVID-19 sequelae in patients with cancer: an analysis from the OnCovid registry. Eur. J. Cancer 170, 10&#x2013;16. 10.1016/j.ejca.2022.03.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2022.03.019</ArticleId><ArticleId IdType="pmc">PMC9040509</ArticleId><ArticleId IdType="pubmed">35576848</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa B. A., da Luz K., Campos S., Lopes G., de Vasconcelos Leitao J. P., Duarte F. (2022). Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? A case series and review of the literature. Hematol. Transfus. Cell Ther. 44, 26&#x2013;31. 10.1016/j.htct.2021.11.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.htct.2021.11.015</ArticleId><ArticleId IdType="pmc">PMC8768508</ArticleId><ArticleId IdType="pubmed">35075445</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Excess Mortality Collaborators (2022). Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet 399, 1513&#x2013;1536. 10.1016/S0140-6736(21)02796-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02796-3</ArticleId><ArticleId IdType="pmc">PMC8912932</ArticleId><ArticleId IdType="pubmed">35279232</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagher H., Chaftari A. M., Subbiah I., Malek A., Jiang Y., Lamie P., et al. (2023). Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period. Elife 12, e81182. 10.7554/eLife.81182</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.81182</ArticleId><ArticleId IdType="pmc">PMC9977271</ArticleId><ArticleId IdType="pubmed">36748905</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai M., Liu D., Liu M., Zhou F., Li G., Chen Z., et al. (2020). Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov. 10, 783&#x2013;791. 10.1158/2159-8290.CD-20-0422</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-0422</ArticleId><ArticleId IdType="pmc">PMC7309152</ArticleId><ArticleId IdType="pubmed">32345594</ArticleId></ArticleIdList></Reference><Reference><Citation>Daly J. L., Simonetti B., Klein K., Chen K. E., Williamson M. K., Anton-Plagaro C., et al. (2020). Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science 370, 861&#x2013;865. 10.1126/science.abd3072</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd3072</ArticleId><ArticleId IdType="pmc">PMC7612957</ArticleId><ArticleId IdType="pubmed">33082294</ArticleId></ArticleIdList></Reference><Reference><Citation>De Cock J. M., Shibue T., Dongre A., Keckesova Z., Reinhardt F., Weinberg R. A. (2016). Inflammation triggers Zeb1-dependent escape from tumor latency. Cancer Res. 76, 6778&#x2013;6784. 10.1158/0008-5472.CAN-16-0608</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-16-0608</ArticleId><ArticleId IdType="pmc">PMC5135644</ArticleId><ArticleId IdType="pubmed">27530323</ArticleId></ArticleIdList></Reference><Reference><Citation>De Winter F. H. R., Hotterbeekx A., Huizing M., Konnova A., Fransen E., Jongers B., et al. (2021). Blood cytokine analysis suggests that SARS-CoV-2 infection results in a sustained tumour promoting environment in cancer patients. Cancers (Basel) 13, 5718. 10.3390/cancers13225718</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13225718</ArticleId><ArticleId IdType="pmc">PMC8616215</ArticleId><ArticleId IdType="pubmed">34830872</ArticleId></ArticleIdList></Reference><Reference><Citation>de Wit E., van Doremalen N., Falzarano D., Munster V. J. (2016). SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523&#x2013;534. 10.1038/nrmicro.2016.81</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2016.81</ArticleId><ArticleId IdType="pmc">PMC7097822</ArticleId><ArticleId IdType="pubmed">27344959</ArticleId></ArticleIdList></Reference><Reference><Citation>du Plessis M., Fourie C., Riedemann J., de Villiers W. J. S., Engelbrecht A. M. (2022). Cancer and covid-19: collectively catastrophic. Cytokine Growth Factor Rev. 63, 78&#x2013;89. 10.1016/j.cytogfr.2021.10.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2021.10.005</ArticleId><ArticleId IdType="pmc">PMC8536488</ArticleId><ArticleId IdType="pubmed">34794863</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore S. (2007). Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35, 495&#x2013;516. 10.1080/01926230701320337</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01926230701320337</ArticleId><ArticleId IdType="pmc">PMC2117903</ArticleId><ArticleId IdType="pubmed">17562483</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum D. C., June C. H. (2020). Cytokine storm. N. Engl. J. Med. 383, 2255&#x2013;2273. 10.1056/NEJMra2026131</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2026131</ArticleId><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Francescangeli F., De Angelis M. L., Zeuner A. (2020). COVID-19: a potential driver of immune-mediated breast cancer recurrence. Breast Cancer Res. 22, 117. 10.1186/s13058-020-01360-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13058-020-01360-0</ArticleId><ArticleId IdType="pmc">PMC7598231</ArticleId><ArticleId IdType="pubmed">33126915</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman T. L., Swartz T. H. (2020). Targeting the NLRP3 inflammasome in severe COVID-19. Front. Immunol. 11, 1518. 10.3389/fimmu.2020.01518</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01518</ArticleId><ArticleId IdType="pmc">PMC7324760</ArticleId><ArticleId IdType="pubmed">32655582</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuertes M. B., Kacha A., Kline J., Woo S. R., Kranz D., Murphy K., et al. (2011). Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J. Exp. Med. 208, 2005&#x2013;2016. 10.1084/jem.20101159</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20101159</ArticleId><ArticleId IdType="pmc">PMC3182064</ArticleId><ArticleId IdType="pubmed">21930765</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallo Marin B., Aghagoli G., Lavine K., Yang L., Siff E., Chiang S., et al. (2021). Predictors of COVID-19 severity: A literature review. Rev. Med. Virol. 31, 1&#x2013;10. 10.1002/rmv.2146</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2146</ArticleId><ArticleId IdType="pmc">PMC7855377</ArticleId><ArticleId IdType="pubmed">32845042</ArticleId></ArticleIdList></Reference><Reference><Citation>Garassino M. C., Whisenant J., Huang L. C., Trama A., Torri V., Agustoni F., et al. (2020). COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 21, 914&#x2013;922. 10.1016/S1470-2045(20)30314-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(20)30314-4</ArticleId><ArticleId IdType="pmc">PMC7292610</ArticleId><ArticleId IdType="pubmed">32539942</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil D., Alcazar C. R., Ale&#x10d;kovi&#x107; M., Polyak K. (2020). Immune escape during breast tumor progression. Cancer Immunol. Res. 8, 422&#x2013;427. 10.1158/2326-6066.CIR-19-0786</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-19-0786</ArticleId><ArticleId IdType="pmc">PMC7138346</ArticleId><ArticleId IdType="pubmed">32238387</ArticleId></ArticleIdList></Reference><Reference><Citation>Grivennikov S. I., Greten F. R., Karin M. (2010). Immunity, inflammation, and cancer. Cell 140, 883&#x2013;899. 10.1016/j.cell.2010.01.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.01.025</ArticleId><ArticleId IdType="pmc">PMC2866629</ArticleId><ArticleId IdType="pubmed">20303878</ArticleId></ArticleIdList></Reference><Reference><Citation>Grivennikov S. I., Karin M. (2010). Inflammation and oncogenesis: a vicious connection. Curr. Opin. Genet. Dev. 20, 65&#x2013;71. 10.1016/j.gde.2009.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gde.2009.11.004</ArticleId><ArticleId IdType="pmc">PMC2821983</ArticleId><ArticleId IdType="pubmed">20036794</ArticleId></ArticleIdList></Reference><Reference><Citation>Grivennikov S. I., Karin M. (2011). Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann. Rheum. Dis. 70 (1), i104&#x2013;i108. 10.1136/ard.2010.140145</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.140145</ArticleId><ArticleId IdType="pubmed">21339211</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo B., Fu S., Zhang J., Liu B., Li Z. (2016). Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci. Rep. 6, 36107. 10.1038/srep36107</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep36107</ArticleId><ArticleId IdType="pmc">PMC5082376</ArticleId><ArticleId IdType="pubmed">27786298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N., et al. (2020). Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718&#x2013;724. 10.1126/science.abc6027</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Ham B., Fernandez M. C., D'Costa Z., Brodt P. (2016). The diverse roles of the TNF axis in cancer progression and metastasis. Trends Cancer Res. 11, 1&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5138060</ArticleId><ArticleId IdType="pubmed">27928197</ArticleId></ArticleIdList></Reference><Reference><Citation>Handy D. E., Castro R., Loscalzo J. (2011). Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation 123, 2145&#x2013;2156. 10.1161/CIRCULATIONAHA.110.956839</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.956839</ArticleId><ArticleId IdType="pmc">PMC3107542</ArticleId><ArticleId IdType="pubmed">21576679</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazarika M., Reddy R., Rai A., Roy P., Iqbal A., Barbhuiyan S., et al. (2022). COVID-19 prevalence and survival outcome in pediatric cancer patients undergoing chemotherapy: A study from tertiary cancer center of north-east India. Asian Pac J. Cancer Care 7, 475&#x2013;480. 10.31557/apjcc.2022.7.3.475-480</Citation><ArticleIdList><ArticleId IdType="doi">10.31557/apjcc.2022.7.3.475-480</ArticleId></ArticleIdList></Reference><Reference><Citation>Haznedaroglu I. C., Malkan U. Y. (2016). Local bone marrow renin-angiotensin system in the genesis of leukemia and other malignancies. Eur. Rev. Med. Pharmacol. Sci. 20, 4089&#x2013;4111.</Citation><ArticleIdList><ArticleId IdType="pubmed">27775788</ArticleId></ArticleIdList></Reference><Reference><Citation>He L., Ding Y., Zhang Q., Che X., He Y., Shen H., et al. (2006). Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J. Pathol. 210, 288&#x2013;297. 10.1002/path.2067</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2067</ArticleId><ArticleId IdType="pmc">PMC7167655</ArticleId><ArticleId IdType="pubmed">17031779</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z., Zhang S. (2021). Tumor-associated macrophages and their functional transformation in the hypoxic tumor microenvironment. Front. Immunol. 12, 741305. 10.3389/fimmu.2021.741305</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.741305</ArticleId><ArticleId IdType="pmc">PMC8481680</ArticleId><ArticleId IdType="pubmed">34603327</ArticleId></ArticleIdList></Reference><Reference><Citation>Hempel L., Piehler A., Pfaffl M. W., Molnar J., Kirchner B., Robert S., et al. (2020). SARS-CoV-2 infections in cancer outpatients- Most infected patients are asymptomatic carriers without impact on chemotherapy. Cancer Med. 9, 8020&#x2013;8028. 10.1002/cam4.3435</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.3435</ArticleId><ArticleId IdType="pmc">PMC7643635</ArticleId><ArticleId IdType="pubmed">33022856</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano T., Murakami M. (2020). COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity 52, 731&#x2013;733. 10.1016/j.immuni.2020.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7175868</ArticleId><ArticleId IdType="pubmed">32325025</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano T. (2021). IL-6 in inflammation, autoimmunity and cancer. Int. Immunol. 33, 127&#x2013;148. 10.1093/intimm/dxaa078</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxaa078</ArticleId><ArticleId IdType="pmc">PMC7799025</ArticleId><ArticleId IdType="pubmed">33337480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271&#x2013;280. 10.1016/j.cell.2020.02.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby P., Lim W. S., Emberson J., Mafham M., Bell J., Linsell L., et al. (2021). Dexamethasone in hospitalized patients with covid-19. N. Engl. J. Med. 384, 693&#x2013;704. 10.1056/nejmoa2021436</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss R. S., Moldawer L. L. (2014). Parallels between cancer and infectious disease. N. Engl. J. Med. 371, 380&#x2013;383. 10.1056/NEJMcibr1404664</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcibr1404664</ArticleId><ArticleId IdType="pubmed">25054723</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidou M., Tragiannidis A., Hatzipantelis E. (2021). Acute Leukemia in children after recent COVID-19 infection. Possible association? Hippokratia 25, 47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8877928</ArticleId><ArticleId IdType="pubmed">35221656</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafarzadeh A., Gosain R., Mortazavi S. M. J., Nemati M., Jafarzadeh S., Ghaderi A. (2022). SARS-CoV-2 infection: A possible risk factor for incidence and recurrence of cancers. Int. J. Hematol. Oncol. Stem Cell Res. 16, 117&#x2013;127. 10.18502/ijhoscr.v16i2.9205</Citation><ArticleIdList><ArticleId IdType="doi">10.18502/ijhoscr.v16i2.9205</ArticleId><ArticleId IdType="pmc">PMC9547773</ArticleId><ArticleId IdType="pubmed">36304732</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson D. E., O'Keefe R. A., Grandis J. R. (2018). Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234&#x2013;248. 10.1038/nrclinonc.2018.8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2018.8</ArticleId><ArticleId IdType="pmc">PMC5858971</ArticleId><ArticleId IdType="pubmed">29405201</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandeel E. Z., Refaat L., Abdel-Fatah R., Samra M., Bayoumi A., Abdellateif M. S., et al. (2021). Could COVID-19 induce remission of acute leukemia? Hematology 26, 870&#x2013;873. 10.1080/16078454.2021.1992117</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/16078454.2021.1992117</ArticleId><ArticleId IdType="pubmed">34719343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazazian H. H., Jr, Moran J. V. (2017). Mobile DNA in health and disease. N. Engl. J. Med. 377, 361&#x2013;370. 10.1056/NEJMra1510092</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1510092</ArticleId><ArticleId IdType="pmc">PMC5980640</ArticleId><ArticleId IdType="pubmed">28745987</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellogg C., Kouznetsova V. L., Tsigelny I. F. (2021). Implications of viral infection in cancer development. Biochim. Biophys. Acta Rev. Cancer. 1876, 188622. 10.1016/j.bbcan.2021.188622</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2021.188622</ArticleId><ArticleId IdType="pubmed">34478803</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M. A., Islam A. B. M. M. K. (2021). SARS-CoV-2 proteins exploit host's genetic and epigenetic mediators for the annexation of key host signaling pathways. Front. Mol. Biosci. 7, 598583. 10.3389/fmolb.2020.598583</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.598583</ArticleId><ArticleId IdType="pmc">PMC7872968</ArticleId><ArticleId IdType="pubmed">33585554</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan M. A., Sany M. R. U., Islam M. S., Islam A. B. M. M. K. (2020). Epigenetic regulator miRNA pattern differences among SARS-CoV, SARS-CoV-2, and SARS-CoV-2 world-wide isolates delineated the mystery behind the epic pathogenicity and distinct clinical characteristics of pandemic COVID-19. Front. Genet. 11, 765. 10.3389/fgene.2020.00765</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2020.00765</ArticleId><ArticleId IdType="pmc">PMC7381279</ArticleId><ArticleId IdType="pubmed">32765592</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaunig J. E., Kamendulis L. M., Hocevar B. A. (2010). Oxidative stress and oxidative damage in carcinogenesis. Toxicol. Pathol. 38, 96&#x2013;109. 10.1177/0192623309356453</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0192623309356453</ArticleId><ArticleId IdType="pubmed">20019356</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobelt D., Zhang C., Clayton-Lucey I., Glauben R., Voss C., Siegmund B., et al. (2020). Pro-inflammatory TNF-&#x3b1; and IFN-&#x3b3; promote tumor growth and metastasis via induction of MACC1. Front. Immunol. 11, 980. 10.3389/fimmu.2020.00980</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00980</ArticleId><ArticleId IdType="pmc">PMC7326113</ArticleId><ArticleId IdType="pubmed">32670264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulbe H., Thompson R., Wilson J., Robinson S., Haheman T., Fatah R., et al. (2007). The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 67, 585&#x2013;592. 10.1158/0008-5472.CAN-06-2941</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-06-2941</ArticleId><ArticleId IdType="pmc">PMC2679985</ArticleId><ArticleId IdType="pubmed">17234767</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari N., Dwarakanath B. S., Das A., Bhatt A. N. (2016). Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 37, 11553&#x2013;11572. 10.1007/s13277-016-5098-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-016-5098-7</ArticleId><ArticleId IdType="pubmed">27260630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamsal A., Andersen S. B., Johansson I., Vietri M., Bokil A., Kurganovs N., et al. (2023). Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer. Cell Commun. Signal 21, 50. 10.1186/s12964-023-01062-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-023-01062-y</ArticleId><ArticleId IdType="pmc">PMC9990226</ArticleId><ArticleId IdType="pubmed">36882786</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J. S., Park S., Jeong H., Ahn J., Choi S., Lee H., et al. (2020). Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci. Immunol. 5, eabd1554. 10.1126/sciimmunol.abd1554</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd1554</ArticleId><ArticleId IdType="pmc">PMC7402635</ArticleId><ArticleId IdType="pubmed">32651212</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Wu M. (2021). Pattern recognition receptors in health and diseases. Signal Transduct. Target Ther. 6, 291. 10.1038/s41392-021-00687-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00687-0</ArticleId><ArticleId IdType="pmc">PMC8333067</ArticleId><ArticleId IdType="pubmed">34344870</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N., Wang X., Lv T. (2020). Prolonged SARS-CoV-2 RNA shedding: not a rare phenomenon. J. Med. Virol. 92, 2286&#x2013;2287. 10.1002/jmv.25952</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25952</ArticleId><ArticleId IdType="pmc">PMC7267144</ArticleId><ArticleId IdType="pubmed">32347980</ArticleId></ArticleIdList></Reference><Reference><Citation>Liapis I., Baritaki S. (2022). COVID-19 vs. Cancer immunosurveillance: A game of thrones within an inflamed microenviroment. Cancers (Basel) 14, 4330. 10.3390/cancers14174330</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14174330</ArticleId><ArticleId IdType="pmc">PMC9455004</ArticleId><ArticleId IdType="pubmed">36077865</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S. C., Tsang N. M., Lee P. J., Sui Y. H., Huang C. H., Liu T. T. (2021). Epstein-barr virus induces adipocyte dedifferentiation to modulate the tumor microenvironment. Cancer Res. 81, 3283&#x2013;3294. 10.1158/0008-5472.CAN-20-3121</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-20-3121</ArticleId><ArticleId IdType="pubmed">33824135</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Lu X., Shi P., Yang G., Zhou Z., Li W., et al. (2020). TNF-&#x3b1; increases breast cancer stem-like cells through up-regulating TAZ expression via the non-canonical NF-&#x3ba;B pathway. Sci. Rep. 10, 1804. 10.1038/s41598-020-58642-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-58642-y</ArticleId><ArticleId IdType="pmc">PMC7000832</ArticleId><ArticleId IdType="pubmed">32019974</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Cao X. (2016). Immunosuppressive cells in tumor immune escape and metastasis. J. Mol. Med. Berl. 94, 509&#x2013;522. 10.1007/s00109-015-1376-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-015-1376-x</ArticleId><ArticleId IdType="pubmed">26689709</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C., Wong P., Klein J., Castro T., Silva J., Sundaram M., et al. (2020). Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584, 463&#x2013;469. 10.1038/s41586-020-2588-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2588-y</ArticleId><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L., Li Q., Cai S., Peng H., Huyan T., Yang H. (2021). The role of NK cells in fighting the virus infection and sepsis. Int. J. Med. Sci. 18, 3236&#x2013;3248. 10.7150/ijms.59898</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.59898</ArticleId><ArticleId IdType="pmc">PMC8364442</ArticleId><ArticleId IdType="pubmed">34400893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q., Pan W., Li R., Liu B., Li C., Xie Y., et al. (2020). Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-&#x3ba;B signaling pathway. Pharmacol. Res. 158, 104850. 10.1016/j.phrs.2020.104850</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2020.104850</ArticleId><ArticleId IdType="pmc">PMC7192119</ArticleId><ArticleId IdType="pubmed">32360580</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma-Lauer Y., Carbajo-Lozoya J., Hein M., Muller M., Deng W., Lei J., et al. (2016). p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. Proc. Natl. Acad. Sci. U. S. A. 113, E5192&#x2013;E5201. 10.1073/pnas.1603435113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1603435113</ArticleId><ArticleId IdType="pmc">PMC5024628</ArticleId><ArticleId IdType="pubmed">27519799</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall M. (2020). The lasting misery of coronavirus long-haulers. Nature 585, 339&#x2013;341. 10.1038/d41586-020-02598-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-02598-6</ArticleId><ArticleId IdType="pubmed">32929257</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattick J. S., Amaral P. P., Carninci P., Carpenter S., Chang H. Y., Chen L. L., et al. (2023). Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat. Rev. Mol. Cell Biol. 24, 430&#x2013;447. 10.1038/s41580-022-00566-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-022-00566-8</ArticleId><ArticleId IdType="pmc">PMC10213152</ArticleId><ArticleId IdType="pubmed">36596869</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondal M., Guo J., He P., Zhou D. (2020). Recent advances of oncolytic virus in cancer therapy. Hum. Vaccin Immunother. 16, 2389&#x2013;2402. 10.1080/21645515.2020.1723363</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1723363</ArticleId><ArticleId IdType="pmc">PMC7644205</ArticleId><ArticleId IdType="pubmed">32078405</ArticleId></ArticleIdList></Reference><Reference><Citation>Monroy-Iglesias M. J., Tremble K., Russell B., Moss C., Dolly S., Sita-Lumsden A., et al. (2022). Long-term effects of COVID-19 on cancer patients: the experience from guy's cancer centre. Future Oncol. 18, 3585&#x2013;3594. 10.2217/fon-2022-0088</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon-2022-0088</ArticleId><ArticleId IdType="pubmed">36172860</ArticleId></ArticleIdList></Reference><Reference><Citation>Montopoli M., Zumerle S., Vector R., Rugge M., Zorzi M., Catapano C., et al. (2020). Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann. Oncol. 31, 1040&#x2013;1045. 10.1016/j.annonc.2020.04.479</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2020.04.479</ArticleId><ArticleId IdType="pmc">PMC7202813</ArticleId><ArticleId IdType="pubmed">32387456</ArticleId></ArticleIdList></Reference><Reference><Citation>Moossavi M., Parsamanesh N., Bahrami A., Atkin S. L., Sahebkar A. (2018). Role of the NLRP3 inflammasome in cancer. Mol. Cancer 17, 158. 10.1186/s12943-018-0900-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-018-0900-3</ArticleId><ArticleId IdType="pmc">PMC6240225</ArticleId><ArticleId IdType="pubmed">30447690</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Cancer Institute (2022). Division of cancer control and population science on 17 november 2022. Available at: https://cancercontrol.cancer.gov/ocs/statistics
.</Citation></Reference><Reference><Citation>Nekooghadam S. M., Moradi A., Karimi Toudeshki K., Pishgahi M. (2021). A case of acute leukemia following remission of COVID-19 infection; an urge to search for a probable association. Arch. Acad. Emerg. Med. 9, e51. 10.22037/aaem.v9i1.1338</Citation><ArticleIdList><ArticleId IdType="doi">10.22037/aaem.v9i1.1338</ArticleId><ArticleId IdType="pmc">PMC8366460</ArticleId><ArticleId IdType="pubmed">34405149</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Connell P., Aldhamen Y. A. (2020). Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses. Hum. Vaccin.Immunother. 16, 2980&#x2013;2991. 10.1080/21645515.2020.1802974</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1802974</ArticleId><ArticleId IdType="pmc">PMC8641610</ArticleId><ArticleId IdType="pubmed">32878546</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;hlund D., Elyada E., Tuveson D. (2014). Fibroblast heterogeneity in the cancer wound. J. Exp. Med. 211, 1503&#x2013;1523. 10.1084/jem.20140692</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20140692</ArticleId><ArticleId IdType="pmc">PMC4113948</ArticleId><ArticleId IdType="pubmed">25071162</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldani S., Petrelli F., Dognini G., Borgonovo K., Parati M., Ghilardi M., et al. (2022). COVID-19 and lung cancer survival: an updated systematic review and meta-analysis. Cancers (Basel) 14, 5706. 10.3390/cancers14225706</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14225706</ArticleId><ArticleId IdType="pmc">PMC9688481</ArticleId><ArticleId IdType="pubmed">36428798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ottaiano A., Scala S., D&#x2019;Alterio C., Trotta A., Bello A., Rea G., et al. (2021). Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection. Ther. Adv. Med. Oncol. 13, 17588359211011455. 10.1177/17588359211011455</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17588359211011455</ArticleId><ArticleId IdType="pmc">PMC8107669</ArticleId><ArticleId IdType="pubmed">33995596</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan P., Ge W., LeiLuo Z. W., Liu Y., Guan Z., et al. (2023). SARS-CoV-2 N protein enhances the anti-apoptotic activity of MCL-1 to promote viral replication. Sig Transduct. Target Ther. 8, 194. 10.1038/s41392-023-01459-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01459-8</ArticleId><ArticleId IdType="pmc">PMC10169150</ArticleId><ArticleId IdType="pubmed">37160897</ArticleId></ArticleIdList></Reference><Reference><Citation>Parasher A. (2021). COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad. Med.J. 97, 312&#x2013;320. 10.1136/postgradmedj-2020-138577</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2020-138577</ArticleId><ArticleId IdType="pmc">PMC10017004</ArticleId><ArticleId IdType="pubmed">32978337</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasin F., Calveri M. M., Calabrese A., Pizzarelli G., Bongiovanni I., Andreoli M., et al. (2020). Oncolytic effect of SARS-CoV-2 in a patient with NK lymphoma. Acta Biomed. 91, e2020047. 10.23750/abm.v91i3.10141</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v91i3.10141</ArticleId><ArticleId IdType="pmc">PMC7716983</ArticleId><ArticleId IdType="pubmed">32921739</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietropaolo V., Prezioso C., Moens U. (2021). Role of virus-induced host cell epigenetic changes in cancer. Int. J. Mol. Sci. 22, 8346. 10.3390/ijms22158346</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22158346</ArticleId><ArticleId IdType="pmc">PMC8346956</ArticleId><ArticleId IdType="pubmed">34361112</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinter M., Jain R. K. (2017). Targeting the renin-angiotensin system to improve cancer treatment: implications for immunotherapy. Sci. Transl. Med. 9, eaan5616. 10.1126/scitranslmed.aan5616</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aan5616</ArticleId><ArticleId IdType="pmc">PMC5928511</ArticleId><ArticleId IdType="pubmed">28978752</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto B. G. G., Oliviera A. E. R., Singh Y., Jimenez L., Goncalves A. N. A., Ogava R. L. T., et al. (2020). ACE2 expression is increased in the lungs of patients With comorbidities associated With severe COVID-19. J. Infect. Dis. 222, 556&#x2013;563. 10.1093/infdis/jiaa332</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa332</ArticleId><ArticleId IdType="pmc">PMC7377288</ArticleId><ArticleId IdType="pubmed">32526012</ArticleId></ArticleIdList></Reference><Reference><Citation>Plummer M., de Martel C., Vignat J., Ferley J., Bray F., Franceschi S. (2016). Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob. Health 4, e609&#x2013;e616. 10.1016/S2214-109X(16)30143-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(16)30143-7</ArticleId><ArticleId IdType="pubmed">27470177</ArticleId></ArticleIdList></Reference><Reference><Citation>Policard M., Jain S., Rego S., Dakshanamurthy S. (2021). Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism. Virus Res. 301, 198464. 10.1016/j.virusres.2021.198464</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2021.198464</ArticleId><ArticleId IdType="pmc">PMC8163696</ArticleId><ArticleId IdType="pubmed">34058265</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., et al. (2020). Dysregulation of immune response in patients With coronavirus 2019 (COVID-19) in wuhan, China. Lancet 71, 762&#x2013;768. 10.1093/cid/ciaa248</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa248</ArticleId><ArticleId IdType="pmc">PMC7108125</ArticleId><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimmanesh I., Shariati L., Dana N., Esmaeli Y., Vaseghi G., Javanmard S. (2022). Cancer occurrence as the upcoming complications of COVID-19. Front. Mol. Biosci. 8, 813175. 10.3389/fmolb.2021.813175</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.813175</ArticleId><ArticleId IdType="pmc">PMC8831861</ArticleId><ArticleId IdType="pubmed">35155571</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman A., Niloofa R., Jayarajah U., De Mel S., Abeysuriya V., Seneviratne S. (2021). Hematological abnormalities in COVID-19: A narrative review. Am. J. Trop. Med. Hyg. 104, 1188&#x2013;1201. 10.4269/ajtmh.20-1536</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.20-1536</ArticleId><ArticleId IdType="pmc">PMC8045618</ArticleId><ArticleId IdType="pubmed">33606667</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapti V., Tsaganos T., Vathiotis I. A., Syrigos N. K., Li P., Poulakou G. (2022). New insights into SARS-CoV-2 and cancer cross-talk: does a novel oncogenesis driver emerge? Vaccines (Basel) 10, 1607. 10.3390/vaccines10101607</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10101607</ArticleId><ArticleId IdType="pmc">PMC9611551</ArticleId><ArticleId IdType="pubmed">36298472</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A. V., Jayadevan R., Sashidharan S. (2021). Long COVID: an overview. Diabetes. Metab. Syndr. 15, 869&#x2013;875. 10.1016/j.dsx.2021.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Rugge M., Zorzi M., Guzzinati S. (2020). SARS-CoV-2 infection in the Italian veneto region: adverse outcomes in patients with cancer. Nat. Cancer 1, 784&#x2013;788. 10.1038/s43018-020-0104-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43018-020-0104-9</ArticleId><ArticleId IdType="pubmed">35122051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan B. M., Pine S. R., Chaturvedi A. K., Caporaso N., Harris C. C. (2014). A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. J. Thorac. Oncol. 9, 1494&#x2013;1503. 10.1097/JTO.0000000000000278</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JTO.0000000000000278</ArticleId><ArticleId IdType="pmc">PMC4272608</ArticleId><ArticleId IdType="pubmed">25170636</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahu A. K., Mathew R., Bhat R., Malhorta C., Nayer J., Aggarwal P., et al. (2021). Steroids use in non-oxygen requiring COVID-19 patients: a systematic review and meta-analysis. QJM 114, 455&#x2013;463. 10.1093/qjmed/hcab212</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcab212</ArticleId><ArticleId IdType="pubmed">34347106</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini G., Aneja R. (2021). Cancer as a prospective sequela of long COVID-19. Bioessays 43, e2000331. 10.1002/bies.202000331</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.202000331</ArticleId><ArticleId IdType="pmc">PMC8206711</ArticleId><ArticleId IdType="pubmed">33914346</ArticleId></ArticleIdList></Reference><Reference><Citation>Saka D., G&#xf6;kalp M., Piyade B., Cevik N. C., Arik Sever E., Unutmaz D., et al. (2020). Mechanisms of T-cell exhaustion in pancreatic cancer. Cancers (Basel) 12, 2274. 10.3390/cancers12082274</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12082274</ArticleId><ArticleId IdType="pmc">PMC7464444</ArticleId><ArticleId IdType="pubmed">32823814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sau A., Lau R., Cabrita M., Nolan E., Crooks P., Visvader J., et al. (2016). Persistent activation of NF-&#x3ba;B in BRCA1-deficient mammary progenitors drives aberrant proliferation and accumulation of DNA damage. Cell Stem Cell 19, 52&#x2013;65. 10.1016/j.stem.2016.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2016.05.003</ArticleId><ArticleId IdType="pmc">PMC6850408</ArticleId><ArticleId IdType="pubmed">27292187</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaller J., Agudo J. (2020). Metastatic colonization: escaping immune surveillance. Cancers (Basel) 12, 3385. 10.3390/cancers12113385</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers12113385</ArticleId><ArticleId IdType="pmc">PMC7697481</ArticleId><ArticleId IdType="pubmed">33207601</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully T., Ettela A., LeRoith D., Gallagher E. (2021). Obesity, type 2 diabetes, and cancer risk. Front. Oncol. 10, 615375. 10.3389/fonc.2020.615375</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.615375</ArticleId><ArticleId IdType="pmc">PMC7884814</ArticleId><ArticleId IdType="pubmed">33604295</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N., Bharara Singh A. (2020). S2 subunit of SARS-nCoV-2 interacts with tumor suppressor protein p53 and BRCA: an in silico study. Transl. Oncol. 13, 100814. 10.1016/j.tranon.2020.100814</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2020.100814</ArticleId><ArticleId IdType="pmc">PMC7324311</ArticleId><ArticleId IdType="pubmed">32619819</ArticleId></ArticleIdList></Reference><Reference><Citation>Slaney C. Y., Rautela J., Parker B. S. (2013). The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Res. 73, 5852&#x2013;5857. 10.1158/0008-5472.CAN-13-1642</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-13-1642</ArticleId><ArticleId IdType="pubmed">24062312</ArticleId></ArticleIdList></Reference><Reference><Citation>Snell L. M., McGaha T. L., Brooks D. G. (2017). Type I interferon in chronic virus infection and cancer. Trends Immunol. 38, 542&#x2013;557. 10.1016/j.it.2017.05.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2017.05.005</ArticleId><ArticleId IdType="pmc">PMC8059441</ArticleId><ArticleId IdType="pubmed">28579323</ArticleId></ArticleIdList></Reference><Reference><Citation>Song W., Mazzieri R., Yang T., Gobe G. C. (2017). Translational significance for tumor metastasis of tumor-associated macrophages and epithelial-mesenchymal transition. Front. Immunol. 8, 1106. 10.3389/fimmu.2017.01106</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01106</ArticleId><ArticleId IdType="pmc">PMC5601389</ArticleId><ArticleId IdType="pubmed">28955335</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiegmann R., Payne C., Kiel M., Stahlman S. (2023). Increased prevalence of overweight and obesity and incidence of prediabetes and type 2 diabetes during the COVID-19 pandemic, active component service members, U.S. Armed forces, 2018 to 2021. MSMR 30, 11&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">36881565</ArticleId></ArticleIdList></Reference><Reference><Citation>Surendran A., Jamalkhah M., Poutou J., Birtch R., Lawson C., Dave J., et al. (2023). Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy via lipid modulation of the tumor microenvironment. Front. Immunol. 14, 1099459. 10.3389/fimmu.2023.1099459</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1099459</ArticleId><ArticleId IdType="pmc">PMC10036842</ArticleId><ArticleId IdType="pubmed">36969187</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagliamento M., Lambertini M., Genovo C., Barisione E., De Maria A., Grosso M., et al. (2020). Call for ensuring cancer care continuity during COVID-19 pandemic. ESMO. Open. 5, e000783. 10.1136/esmoopen-2020-000783</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/esmoopen-2020-000783</ArticleId><ArticleId IdType="pmc">PMC7228560</ArticleId><ArticleId IdType="pubmed">32381594</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnquist C., Ryan B. M., Horikawa I., Harris B. T., Harris C. C. (2020). Cytokine storms in cancer and COVID-19. Cancer Cell 38, 598&#x2013;601. 10.1016/j.ccell.2020.09.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2020.09.019</ArticleId><ArticleId IdType="pmc">PMC7531591</ArticleId><ArticleId IdType="pubmed">33038939</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas A. J., Harris C. C. (2016). Biomarker development in the precision medicine era: lung cancer as a case study. Nat. Rev. Cancer 16, 525&#x2013;537. 10.1038/nrc.2016.56</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc.2016.56</ArticleId><ArticleId IdType="pmc">PMC6662593</ArticleId><ArticleId IdType="pubmed">27388699</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter M., Liang S., Ghosh S., Hornsby P. J., Li R. (2009). Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 28, 2745&#x2013;2755. 10.1038/onc.2009.130</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2009.130</ArticleId><ArticleId IdType="pmc">PMC2806057</ArticleId><ArticleId IdType="pubmed">19483720</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Hu B., Hu C., Zhu F., Zhang J., Wang B., et al. (2020a). Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus-infected pneumonia in wuhan, China. JAMA 323, 1061&#x2013;1069. 10.1001/jama.2020.1585</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Kang X., Chen K. S., Jehng T., Jones L., Chen J., et al. (2020b). An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat. Commun. 11, 1395. 10.1038/s41467-020-15229-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15229-5</ArticleId><ArticleId IdType="pmc">PMC7070065</ArticleId><ArticleId IdType="pubmed">32170083</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Zhao J., Zhang L., Wei F., Lian Y., Wu Y., et al. (2017). Role of tumor microenvironment in tumorigenesis. J. Cancer 8, 761&#x2013;773. 10.7150/jca.17648</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.17648</ArticleId><ArticleId IdType="pmc">PMC5381164</ArticleId><ArticleId IdType="pubmed">28382138</ArticleId></ArticleIdList></Reference><Reference><Citation>Watowich M. B., Gilbert M. R., Larion M. (2023). T cell exhaustion in malignant gliomas. Trends Cancer 9, 270&#x2013;292. 10.1016/j.trecan.2022.12.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trecan.2022.12.008</ArticleId><ArticleId IdType="pmc">PMC10038906</ArticleId><ArticleId IdType="pubmed">36681605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga W. J., Rhodes A., Cheng A. C., Peacock S. J., Prescott H. C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 324, 782&#x2013;793. 10.1001/jama.2020.12839</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiese O. J., Allwood B. W., Zemlin A. E. (2020). COVID-19 and the renin-angiotensin system (RAS): A spark that sets the forest alight? Med. Hypotheses 144, 110231. 10.1016/j.mehy.2020.110231</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110231</ArticleId><ArticleId IdType="pmc">PMC7468676</ArticleId><ArticleId IdType="pubmed">33254538</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk A. J., Rustagi A., Zhao N., Roque J., Martinez-Colon G., McKechnie J., et al. (2020). A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med. 26, 1070&#x2013;1076. 10.1038/s41591-020-0944-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0944-y</ArticleId><ArticleId IdType="pmc">PMC7382903</ArticleId><ArticleId IdType="pubmed">32514174</ArticleId></ArticleIdList></Reference><Reference><Citation>Wo&#x17a;niak K., Sachs W., Boguradzki P., Basak G. W., Stec R. (2021). Chemotherapy during active SARS-CoV-2 infection: A case report and review of the literature. Front. Oncol. 11, 662211. 10.3389/fonc.2021.662211</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.662211</ArticleId><ArticleId IdType="pmc">PMC8072114</ArticleId><ArticleId IdType="pubmed">33912468</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W., Cheng Y., Zhou H., Sun C., Zhang S. (2023). The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics. Virol. J. 20, 6. 10.1186/s12985-023-01968-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-023-01968-6</ArticleId><ArticleId IdType="pmc">PMC9831023</ArticleId><ArticleId IdType="pubmed">36627683</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z., Liu J., Shi D., Chen W., Li J., Yan R., et al. (2020). Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int. J. Biol. Sci. 16, 2382&#x2013;2391. 10.7150/ijbs.47652</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.47652</ArticleId><ArticleId IdType="pmc">PMC7378642</ArticleId><ArticleId IdType="pubmed">32760206</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing F., Saidou J., Watabe K. (2010). Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front. Biosci. 15, 166&#x2013;179. 10.2741/3613</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/3613</ArticleId><ArticleId IdType="pmc">PMC2905156</ArticleId><ArticleId IdType="pubmed">20036813</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahav D., Yelin D., Eckerle I., Eberhardt C., Wang J., Cao B., et al. (2021). Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clin. Microbiol. Infect. 27, 315&#x2013;318. 10.1016/j.cmi.2020.11.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.11.028</ArticleId><ArticleId IdType="pmc">PMC7718119</ArticleId><ArticleId IdType="pubmed">33285276</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap J. K. Y., Moriyama M., Iwasaki A. (2020). Inflammasomes and pyroptosis as therapeutic targets for COVID-19. J. Immunol. 205, 307&#x2013;312. 10.4049/jimmunol.2000513</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2000513</ArticleId><ArticleId IdType="pmc">PMC7343621</ArticleId><ArticleId IdType="pubmed">32493814</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye M., Song Y., Pan S., Chu M., Wang Z. W., Zhu X. (2020). Evolving roles of lysyl oxidase family in tumorigenesis and cancer therapy. Pharmacol. Ther. 215, 107633. 10.1016/j.pharmthera.2020.107633</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2020.107633</ArticleId><ArticleId IdType="pubmed">32693113</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan B., Liu H. Q., Yang Z. R., Chen Y. X., Liu Z. Y., Zhang K., et al. (2020). Recurrence of positive SARS-CoV-2 viral RNA in recovered COVID-19 patients during medical isolation observation. Sci. Rep. 10, 11887. 10.1038/s41598-020-68782-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-68782-w</ArticleId><ArticleId IdType="pmc">PMC7368008</ArticleId><ArticleId IdType="pubmed">32681141</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Litvinova M., Wang W., Wang Y., Deng X., Chen J., et al. (2020). Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside hubei province, China: a descriptive and modelling study. Lancet Infect. Dis. 20, 793&#x2013;802. 10.1016/S1473-3099(20)30230-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30230-9</ArticleId><ArticleId IdType="pmc">PMC7269887</ArticleId><ArticleId IdType="pubmed">32247326</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Richards A., Barrasa M., Hughes S., Young R., Jaenisch R. (2021). Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. Proc. Natl. Acad. Sci. U. S. A. 118, e2105968118. 10.1073/pnas.2105968118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2105968118</ArticleId><ArticleId IdType="pmc">PMC8166107</ArticleId><ArticleId IdType="pubmed">33958444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z., Ren L., Zhang L., Zhong J., Xiao Y., Jia Z., et al. (2020). Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell. Host Microbe 27, 883&#x2013;890. 10.1016/j.chom.2020.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.017</ArticleId><ArticleId IdType="pmc">PMC7196896</ArticleId><ArticleId IdType="pubmed">32407669</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>